The drug works. The science is sound. But access remains the barrier.
A clinical milestone quietly announced at a major oncology conference has redefined the horizon for patients with advanced lung cancer: a targeted therapy now shows that more than half of those treated remain free of disease progression after seven years, a duration once unimaginable for this diagnosis. The science, built on decades of molecular understanding, has outpaced the systems meant to deliver it. In Brazil, where over 35,000 people receive this diagnosis each year and nine in ten learn of it only at an advanced stage, the distance between what medicine can offer and what patients can reach remains one of the defining tensions of modern public health.
- A seven-year follow-up study has shattered previous expectations for advanced lung cancer survival, with the median point of disease progression never reached during the entire observation period.
- The drug reduces the risk of cancer spreading to the brain by 94 percent — a figure that reframes one of the most feared complications of the disease.
- Brazil's oncology system is under acute strain: nearly half of patients wait over two months to begin treatment, and more than half of affected families are forced to relocate to access specialized care.
- Judicial pressure has become a structural feature of drug access, costing the federal government R$3.2 billion in a single year to fulfill court-ordered medication provisions.
- A 51 percent rise in colorectal cancer among adults under 50 is adding urgency to calls for expanded genetic screening and earlier intervention protocols.
- The government is moving toward large-scale screening initiatives and a Patient Navigation Program, but the gap between policy design and patient reality remains wide and consequential.
Em junho, durante o congresso da Sociedade Americana de Oncologia Clínica, a Pfizer apresentou dados de sete anos do estudo CROWN que mudaram o que se entende por sobrevivência no câncer de pulmão avançado. Cinquenta e cinco por cento dos pacientes com mutação ALK tratados com lorlatinibe permaneceram vivos sem progressão da doença — e o tempo mediano de sobrevivência sequer foi atingido ao longo do período de acompanhamento. O medicamento reduziu em 81% o risco de morte ou piora clínica em relação à terapia anterior, e em 94% o risco de metástase cerebral. Para o investigador principal do estudo, esse nível de benefício sustentado a partir de um comprimido diário teria parecido impossível uma década atrás.
Mas o avanço científico encontra uma realidade dura no Brasil. São mais de 35 mil novos casos de câncer de pulmão por ano, com 90% dos diagnósticos feitos em estágio avançado. Quase metade dos pacientes espera mais de dois meses para iniciar a quimioterapia, e 57% das famílias precisam se mudar de cidade para acessar centros especializados. O sistema público enfrenta limitações estruturais que tornam o caminho entre a descoberta científica e o leito do paciente longo e incerto.
A judicialização do acesso a medicamentos já consome 3,2 bilhões de reais anuais do governo federal, com 60% dos casos envolvendo remédios que já deveriam estar disponíveis pelo sistema público. Outros cânceres revelam padrões semelhantes de avanço e restrição: combinações terapêuticas promissoras surgem na urologia e na próstata, enquanto o câncer colorretal registra alta de 51% entre menores de 50 anos na última década.
O governo prepara a expansão do rastreamento com teste de sangue oculto nas fezes para 40 milhões de brasileiros, e a Política Nacional de Prevenção e Controle do Câncer, de 2023, prevê assistência farmacêutica e um Programa de Navegação do Paciente. São tentativas concretas de encurtar a distância entre o que a medicina conquistou e o que o paciente consegue, de fato, acessar. O lorlatinibe funciona. A ciência é sólida. A pergunta que permanece, para a maioria dos 35 mil brasileiros diagnosticados a cada ano, é se chegarão ao tratamento a tempo.
A new drug has quietly rewritten what advanced lung cancer means for the people who have it. At the American Society of Clinical Oncology conference in June, Pfizer presented seven-year follow-up data from the CROWN trial showing that 55 percent of patients carrying the ALK mutation and treated with lorlatinibe remained alive without disease progression. The median survival time—the point at which half the patients would be expected to have worsened—was never reached during the study period. For a disease that once meant a countdown, this is a threshold moment.
The numbers carry weight because they are measured against what came before. The drug reduced the risk of death or clinical decline by 81 percent compared to crizotinibe, the previous standard therapy. More striking still: the risk of cancer spreading to the brain dropped by 94 percent. Lorlatinibe was engineered as a third-generation molecule specifically to penetrate the central nervous system and overcome the resistance that tumors develop against earlier treatments. Tony Shu-Kam Mok, the study's lead investigator and chief of oncology at the Chinese University of Hong Kong, noted that observing this level of sustained benefit from a daily oral medication would have seemed impossible a decade ago.
But the triumph of the science collides hard with the reality of access. Brazil records more than 35,000 new lung cancer cases annually, yet nine out of every ten patients receive their diagnosis only when the disease has already advanced. The Instituto Nacional de Câncer estimates this late-stage presentation directly drives the country's high mortality rate. Meanwhile, 47 percent of patients wait more than two months after diagnosis before beginning chemotherapy. For 57 percent of families, that delay forces relocation to another city in search of specialized treatment centers. The public health system struggles with supply shortages and structural limits that make the gap between breakthrough and bedside feel like a chasm.
The access problem extends beyond lung cancer. Judicial intervention has become routine: the federal government spent 3.2 billion reais in a single year fulfilling court orders for medication provision, with 60 percent of those cases involving drugs already incorporated into the public health system. The system is being pulled in two directions at once—innovation accelerating in laboratories while infrastructure strains under the weight of demand.
Other cancers are showing similar patterns of progress and constraint. The EV-302 trial demonstrated that combining enfortumab vedotina with pembrolizumab improved outcomes in urothelial carcinoma, with 44 percent of patients alive after three and a half years and 30 percent achieving complete remission. In prostate cancer, multiparametric MRI has become the central tool for directing biopsies, reducing unnecessary procedures. But colorectal cancer presents an alarm: incidence among people under 50 has risen 51 percent over the past decade, prompting increased focus on genetic mapping to identify hereditary syndromes and aggressive mutations like BRAF V600E.
The Brazilian government is preparing to expand screening efforts. A blood-based fecal occult test is expected to become part of public health strategy, with the goal of reaching 40 million Brazilians between 50 and 75 years old. The National Cancer Prevention and Control Policy, enacted in 2023, includes provisions for pharmaceutical assistance and a Patient Navigation Program designed to guide people through treatment stages. These are structural attempts to narrow the gap between what medicine can do and what patients can actually access.
What lorlatinibe represents, then, is not simply a medical victory but an incomplete one. The drug works. The science is sound. But for most of the 35,000 Brazilians diagnosed with lung cancer each year, the question is not whether the treatment exists—it is whether they will reach it in time.
Notable Quotes
Observing this level of benefit to long-term survival with a daily oral therapy would have been difficult to imagine a decade ago— Tony Shu-Kam Mok, lead investigator, Chinese University of Hong Kong
The Hearth Conversation Another angle on the story
Why does a seven-year survival number matter so much? People live longer all the time.
Because with advanced lung cancer, you're usually talking about months, not years. The fact that the median progression-free survival wasn't even reached means more than half the patients are still stable after seven years. That's not incremental—that's a fundamental shift in what the disease looks like.
And the brain metastasis reduction—94 percent—that's the drug's special trick?
Exactly. Earlier drugs couldn't cross the blood-brain barrier effectively. Tumors would hide there and grow. Lorlatinibe was designed to penetrate the central nervous system directly. It's precision engineering solving a specific problem that killed people.
So why isn't this a complete victory story?
Because in Brazil, 90 percent of lung cancer patients are diagnosed when it's already advanced. And then they wait two months on average before treatment starts. The drug exists, but the infrastructure to deliver it doesn't match the need.
The 57 percent of families relocating—that's a real number?
Yes. Public treatment centers are overwhelmed and undersupplied. If you live outside a major city and get diagnosed, you often have to move your whole family to access care. That's not a medical problem anymore—it's a social one.
What about the judicial intervention angle? Three billion reais for medication?
The courts are filling a gap the system left open. Patients sue because they can't get drugs through normal channels, even drugs the government has already approved. It's a sign the system is broken at the distribution level, not the policy level.
Is colorectal cancer rising because of something new, or just better detection?
The 51 percent jump in under-50s is real and unexplained. It's not just screening catching more cases. Something is changing in the disease pattern itself, and we don't fully understand why yet.